在2023年美国癌症研究协会年会(AACR 2023)和2022年癌症免疫治疗学会年会(SITC 2022)上公布的临床前数据显示,ATN-031可以纳摩尔级别亲和力与CD24特异性结合并阻断CD24与Siglec-10的互动。此外,ATN-031可诱导皮摩尔EC50水平的高效吞噬作用,并促进巨噬细胞分泌促炎细胞因子。 关于Antennova 德琪医药的美国全资子公司Antenno...
德琪医药在去年SITC会议上披露了ATG-031的临床前研究数据。ATG-031可以有效阻断CD24与Siglec-10的相互作用,IC50为13.12nM。功能学研究表明,ATG-031可以有效增强TAM对肿瘤细胞的吞噬效应。 小鼠肿瘤模型研究表明,ATG-031表现出显著的单药抗肿瘤活性,3mg/kg剂量治疗MC38结肠癌模型,8只小鼠中有4只小鼠肿瘤完全消退。CT...
doi:10.1136/jitc-2022-SITC2022.0482Background By overexpressing anti-phagocytic surface proteins, often known as "don't eat me" signals, cancer cells can evade macrophage-mediated elimination. Therapeutic antibodies targeting "don't eat me" protein, such as CD47, demonstrates promising anti-tumor ...
1337The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignanciesdoi:10.1136/jitc-2023-SITC2023.1337Background CD24 is a small, highly glycosylated cell adhesion protein that ...